After seven months of resisting a takeover bid from Canada’s Valeant Pharmaceuticals International, Allergan Inc. agreed on Nov. 17 to be acquired by Irish generic drug maker Actavis plc in a cash and stock deal valued at $66 billion. It was the largest M&A deal announced to date in 2014.
Cleary Gottlieb Steen & Hamilton and Weil, Gotshal & Manges are advising Actavis, while Latham & Watkins and Wachtell, Lipton, Rosen & Katz are representing Irvine, Calif.-based Allergan.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
